CORONA Remedies (CORONA) Q4 25/26 earnings summary

Executive summary

• Achieved strong revenue growth of 20.2% in Q4FY26 and 17.3% in FY26 year-over-year, driven by robust brand performance and execution excellence.

• Annual consolidated and standalone financial results for the year ended March 31, 2026, were audited and present a true and fair view in accordance with Indian Accounting Standards.

• Quarterly results for March 31, 2026, were reviewed with no material misstatements identified.

• Strategic acquisitions, including Wokadine and seven brands from Bayer Zydus, expanded presence in key therapeutic areas and infertility segment.

• The company completed its IPO and listed on NSE and BSE on December 15, 2025.

Financial highlights

• FY26 revenue reached INR 1,413.83 Cr, up from INR 1,202.35 Cr in FY25; Q4FY26 revenue was INR 353.1 Cr, up 20.2%.

• EBITDA for FY26 was INR 293.4 Cr (22.3% growth), with a margin of 20.9% (+85 bps YoY).

• Adjusted PAT for FY26 was INR 199.4 Cr, up 33.4% YoY, with a margin of 14.2% (+172 bps).

• Consolidated net profit after tax for FY26 was INR 185.12 Cr, compared to INR 149.43 Cr in FY25.

• Gross margin improved to 81.4% in FY26 from 80.2% in FY25.

Outlook and guidance

• Plans to increase domestic market share, expand into new therapeutic areas, and deepen presence in chronic therapies.

• Focus on product launches addressing unmet needs, strategic acquisitions, and international market expansion.

• Board recommended a dividend of ₹10 per fully paid equity share for FY26, subject to shareholder approval.

• The company continues to monitor regulatory changes, especially regarding labour codes, for future financial impact.